Cytomegalovirus Disease
Conditions
Interventions
Ganciclovir Prophylaxis group:None
Sponsors
First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who underwent allogeneic kidney transplantation for the first time at our hospital, and receive antiviral drug treatment with ganciclovir, include both adults and children; 2.Patients who could tolerate oral medications and have good compliance; 3.Patients who had complete information and was willing to have regular follow-up visits, undewent routine blood biochemistry tests, liver and kidney function tests, and blood drug concentration monitoring (at weeks 2, 4, 8, and 12 after using GCV).
Exclusion criteria
Exclusion criteria: 1. All patients with contraindications to GCV usage, or those who had not strictly adhered to the prescribed medication regimen, or who have been lost to follow-up for various reasons; 2.Patients receiving treatments such as hemodialysis or dehydration during GCV therapy that significantly interfere with normal pharmacokinetics; 3.Multi-organ transplant recipients; 4.Human immunodeficiency virus carriers; 5.Patients with uncontrollable severe infections, including bacterial, tuberculosis, fungal, and viral infections; 6.Pregnant individuals or those planning to conceive within the next year; 7.Patients with the following conditions: malignancies, diabetes, chronic enteritis, chronic pneumonia, abnormal liver function, cirrhosis, heart and lung insufficiency, and severe gastrointestinal diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ganciclovir plasma concentration;Peripheral blood mononuclear cell intracellular ganciclovir triphosphate concentration; | — |
Countries
China
Contacts
Public ContactXia Zhu
First Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed